Pegfilgrastim Biosimilars Global Market Report 2022 – By Application (Chemotherapy Treatment, Transplantation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026

Starting Price : $5000.00 | Pages : 150 | Published : February 2022 | SKU CODE : | Delivery Time: 2-3 business days | Format :


The pegfilgrastim biosimilars market consists of the sales of pegfilgrastim biosimilars and related services offered by the companies that develop and manufacture them. Pegfilgrastim is a version of filgrastim (Neupogen), used to increase the production of infection-fighting white blood cells for the treatment of cancer patients undergoing chemotherapy. Pegfilgrastim biosimilars find their applications in reducing infection for patients undergoing anticancer therapy.

 

The different applications in pegfilgrastim biosimilars market are chemotherapy treatment, transplantation and others. Chemotherapy is a cancer treatment that involves the administration of one or more anti-cancer medications as part of a defined protocol. The various distribution channels include hospital pharmacies, retail pharmacies and mail-order pharmacies.

 

The global pegfilgrastim biosimilars market size is expected to grow from $1.17 billion in 2021 to $1.28 billion in 2022 at a compound annual growth rate (CAGR) of 10%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The pegfilgrastim biosimilars market is expected to reach $1.92 billion in 2026 at a CAGR of 10.6%.

 

Government initiatives for the development of biosimilars are expected to drive the pegfilgrastim biosimilars market. Governments worldwide are focusing on the development of biosimilars attributing to their cost-effective nature. The US Food and Drug Administration (FDA) launched a Biosimilar Action Plan, to increase treatment options. The Australian government is committed to the Biosimilar Awareness Initiative and they improved their commitment by supporting the Generic and Biosimilar Medicines Association through a grant of $5 million to accept increased general biosimilar education and activities that promote the suitable dispensing, prescription and use of biosimilar medicines. Hence, the government initiatives for the development of biosimilars aids in the increased production and awareness which in turn supported the growth of the pegfilgrastim biosimilars market.

 

During the forecast period the pegfilgrastim biosimilars market was restrained by the low number of drug approvals by the FDA. The market currently only has 4 drugs approved for treatment, thus restraining the growth of the market. This can be attributed to strict standards for manufacturing and high drug efficacy standards set by the regulatory bodies for approval of this therapy, thus increasing the time required for approval and limiting the growth of the market.  

Companies in the pegfilgrastim biosimilars market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with each other as well as academic and research institutions in this market by way of partnerships, in or out licensing deals, this trend has been increasing over the recent years. For instance, in April 2020, Biocon, an India based biopharmaceutical company partnered with Mylan, a US based generic and specialty pharmaceuticals company to introduce Fulphila, biosimilar pegfilgrastim in Australia. Fulphila has been licenced by the Therapeutic Goods Administration for the therapy of oncology patients who have had chemotherapy in order to shorten the length of acute neutropenia and hence the risk of infection, as evidenced by febrile neutropenia.  

In January 2019, Kashiv Pharma, a US-based pharmaceutical research and drug delivery company acquired Adello Biologics LLC for an undisclosed amount. The purchase of Adello will result in the formation of a fully integrated biosciences firm with a strong growth platform. Kashiv Pharmato will be able to produce products with real clinical distinction and a compelling value offering for patients, clinicians, and payers because to its combined experience in small and big compounds, peptides, proteins, and monoclonal antibodies. Adello Biologics, LLC is a US-based company that offers pegfilgrastim biosimilars.  

Major players in the pegfilgrastim biosimilars market are Mylan, Biocon, Mundipharma, Pfizer, Sandoz, Coherus, Intas Pharmaceuticals and Fresenius Kabi.

 

North America was the largest region in the pegfilgrastim biosimilars market in 2021. The Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

 

The countries covered in the pegfilgrastim biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

 

The global pegfilgrastim biosimilars market is segmented -

1) By Application: Chemotherapy Treatment, Transplantation, Others

 

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies

    Table Of Contents

    1. Executive Summary

    2. Pegfilgrastim Biosimilars Market Characteristics

    3. Pegfilgrastim Biosimilars Market Trends And Strategies

    4. Impact Of COVID-19 On Pegfilgrastim Biosimilars

    5. Pegfilgrastim Biosimilars Market Size And Growth

    5.1. Global Pegfilgrastim Biosimilars Historic Market, 2016-2021, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Pegfilgrastim Biosimilars Forecast Market, 2021-2026F, 2031F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Pegfilgrastim Biosimilars Market Segmentation

    6.1. Global Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Chemotherapy Treatment

    Transplantation

    Others

    6.2. Global Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Hospital pharmacies

    Retail pharmacies

    Mail-Order pharmacies

    7. Pegfilgrastim Biosimilars Market Regional And Country Analysis

    7.1. Global Pegfilgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    7.2. Global Pegfilgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    8. Asia-Pacific Pegfilgrastim Biosimilars Market

    8.1. Asia-Pacific Pegfilgrastim Biosimilars Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    9. China Pegfilgrastim Biosimilars Market

    9.1. China Pegfilgrastim Biosimilars Market Overview

    9.2. China Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

    10. India Pegfilgrastim Biosimilars Market

    10.1. India Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    11. Japan Pegfilgrastim Biosimilars Market

    11.1. Japan Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    12. Australia Pegfilgrastim Biosimilars Market

    12.1. Australia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    13. Indonesia Pegfilgrastim Biosimilars Market

    13.1. Indonesia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    14. South Korea Pegfilgrastim Biosimilars Market

    14.1. South Korea Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    15. Western Europe Pegfilgrastim Biosimilars Market

    15.1. Western Europe Pegfilgrastim Biosimilars Market Overview

    15.2. Western Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    16. UK Pegfilgrastim Biosimilars Market

    16.1. UK Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    17. Germany Pegfilgrastim Biosimilars Market

    17.1. Germany Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    18. France Pegfilgrastim Biosimilars Market

    18.3. France Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    19. Eastern Europe Pegfilgrastim Biosimilars Market

    19.1. Eastern Europe Pegfilgrastim Biosimilars Market Overview

    19.2. Eastern Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    20. Russia Pegfilgrastim Biosimilars Market

    20.1. Russia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    21. North America Pegfilgrastim Biosimilars Market

    21.1. North America Pegfilgrastim Biosimilars Market Overview

    21.2. North America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    22. USA Pegfilgrastim Biosimilars Market

    22.1. USA Pegfilgrastim Biosimilars Market Overview

    22.2. USA Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    23. South America Pegfilgrastim Biosimilars Market

    23.1. South America Pegfilgrastim Biosimilars Market Overview

    23.2. South America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    24. Brazil Pegfilgrastim Biosimilars Market

    24.1. Brazil Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    25. Middle East Pegfilgrastim Biosimilars Market

    25.1. Middle East Pegfilgrastim Biosimilars Market Overview

    25.2. Middle East Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    26. Africa Pegfilgrastim Biosimilars Market

    26.1. Africa Pegfilgrastim Biosimilars Market Overview

    26.2. Africa Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    27. Pegfilgrastim Biosimilars Market Competitive Landscape And Company Profiles

    27.1. Pegfilgrastim Biosimilars Market Competitive Landscape

    27.2. Pegfilgrastim Biosimilars Market Company Profiles

    27.2.1. Mylan

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Biocon

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Mundipharma

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Pfizer

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. Sandoz

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Pegfilgrastim Biosimilars Pipeline Analysis

    29. Key Mergers And Acquisitions In The Pegfilgrastim Biosimilars Market

    30. Pegfilgrastim Biosimilars Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Research Inquiries

    31.4. The Business Research Company

    31.5. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2016-2021, $ Billion
  • Table 2: Global Forecast Market Growth, 2021-2026F, 2031F, $ Billion
  • Table 3: Global Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 4: Global Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 5: Global Pegfilgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 6: Global Pegfilgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 7: Asia-Pacific, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 8: China, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 9: India, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 10: Japan, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 11: Australia, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 12: Indonesia, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 13: South Korea, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 14: Western Europe, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 15: UK, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 16: Germany, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 17: France, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 18: Eastern Europe, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 19: Russia, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 20: North America, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 21: USA, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 22: South America, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 23: Brazil, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 24: Middle East, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 25: Africa, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 26: Mylan Financial Performance
  • Table 27: Biocon Financial Performance
  • Table 28: Mundipharma Financial Performance
  • Table 29: Pfizer Financial Performance
  • Table 30: Sandoz Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2016-2021, $ Billion
  • Figure 2: Global Forecast Market Growth, 2021-2026F, 2031F, $ Billion
  • Figure 3: Global Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 4: Global Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 5: Global Pegfilgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 6: Global Pegfilgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 7: Asia-Pacific, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 8: China, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 9: India, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 10: Japan, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 11: Australia, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 12: Indonesia, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 13: South Korea, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 14: Western Europe, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 15: UK, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 16: Germany, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 17: France, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 18: Eastern Europe, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 19: Russia, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 20: North America, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 21: USA, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 22: South America, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 23: Brazil, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 24: Middle East, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 25: Africa, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 26: Mylan Financial Performance
  • Figure 27: Biocon Financial Performance
  • Figure 28: Mundipharma Financial Performance
  • Figure 29: Pfizer Financial Performance
  • Figure 30: Sandoz Financial Performance
Global Contract Research And Manufacturing Services (CRAMS) Market Size, Forecasts, And Opportunities – Includes CRAMS Market Overview
Global Pulmonary Arterial Hypertension Market Overview And Prospects – Includes Pulmonary Arterial Hypertension Market Share
Global Botanical Supplements Market Outlook, Opportunities And Strategies – Includes Botanical Supplements Industry
Global Pharmacovigilance Market Size, Forecasts, And Opportunities – Includes Pharmacovigilance Market Share
Global Herbal Supplements Market Outlook, Opportunities And Strategies – Includes Herbal Supplements Market Size
Global Hyperphosphatemia Treatment Market Outlook, Opportunities And Strategies – Including Hyperphosphatemia Treatment Algorithm
Global Multivitamin Capsules And Tablets Market Size, Forecasts, And Opportunities – Includes Vitamin Industry Trends
Global Naloxone Spray Market Overview And Prospects – Including pharmacies
Biosimilars Global Market Report 2022 – By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins), By Types (Human Growth Hormone, Erythropoietin, Monoclonal antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor), By Application (Oncology, Chronic and Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2022 – By Product (Adalimumab Biosimilars (Exemptia, Mabura, Hyrimoz, Hadlima, Abrilada, Others), Infliximab Biosimilars (Inflectra, Renflexis, Ixifi, Avsola), Cipleumab (Erelzi, Eticovo)), By Application (Crohn’S Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Biosimilar Hormones Global Market Report 2022 – By Type (Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars), By Application (Research & Biotechnology, Diagnostics, Biocatalysts, Therapeutics), By Distribution Channel (Hospital And Retail Pharmacy, Online Pharmacy/epharmacy, Speciality Clinics) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Filgrastim Biosimilars Global Market Report 2022 – By Application (Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Type Of Manufacturing (In-House Manufacturing, Contract Manufacturing Oraganization) – Market Size, Trends, And Global Forecast 2022-2026
View Report
G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2022 – By Type (Lenograstim (Granocyte), Filgrastim (Neupogen, Zarzio, Nivestim, Accofil), Long Acting (Pegylated) Filgrastim (Pegfilgrastim, Neulasta, Pelmeg, Ziextenco), Lipegfilgrastim (Lonquex)), By Application (Oncological Diseases, Blood Disorders, Growth Hormone Deficiencies, Chronic And Autoimmune Disorders, Others), By Product: Tablet, Capsule, Others) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Neutropenia Biologic Drug Treatment Global Market Report 2022 – By Drug Type (Filgrastim, Pegfilgrastim, Lenograstim, Lipegfilgrastim, Sargramostim), By Treatment Type (Antibiotic Drugs, Granulocyte-Colony-Stimulating Factor (G-CSF), Antifungal Drugs), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Oncology Biosimilars Global Market Report 2022 – By Drug Type (Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)), By Cancer Type (Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer), By Distribution Type (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Market Size, Trends, And Global Forecast 2022-2026
View Report